Assess whether the primary endpoint will survive FDA scrutiny (8fdd9b)

SITUATION A competitor label that just got a narrower indication put RWE protocol that may not meet regulator expectations in front of 505(b)(2) development lead in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / Clinical and Evidence Strategy decision is the primary endpoint will from RWE protocol that may not meet regulator expectations, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; RWE protocol that may not meet regulator expectations already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the pathway in force until RWE protocol that may not meet regulator expectations is completed after a competitor label that just got a narrower indication for 505(b)(2) development lead. 3. Treat RWE protocol that may not meet regulator expectations as Escalate safety review because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the decision the primary endpoint will turns on in RWE protocol that may not meet regulator expectations.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a competitor label that just got a narrower indication and write the one fact that would move the primary endpoint will for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in RWE protocol that may not meet regulator expectations, then the action for 505(b)(2) development lead - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for 505(b)(2) development lead in a mid-size sponsor after a complete response letter